The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Rationale of TRANSFORM: liso-cel vs SOC in patients with high-risk R/R NHL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, discusses the rationale of the TRANSFORM study comparing the safety and efficacy of lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) as a second-line treatment in patients with high-risk relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) (NCT03575351). This trial was based on the results of the TRANSCEND-NHL-001 trial (NCT02631044) which led to the approval of liso-cel in the third-line setting. Dr Kamdar explains that the preliminary results of TRANSFORM are promising and could lead to the approval of this chimeric antigen receptor (CAR) T-cell therapy in the second-line setting. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
